Implementing Newer Therapies to Improve Economic and Clinical Outcomes in Patients with Rheumatoid Arthritis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 15, 2019 to January 31, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
AbbVie

Description:
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. The disease may also affect other parts of the body, which results in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. There is no cure for RA. Treatment includes controlling the pain, during flair ups especially, and preventing joint damage. Many patients will have an inadequate response or can become intolerant to the widely used anti-TNF therapies. Consequently, the patient’s health-related quality of life may continue to be significantly reduced. Fortunately, new and emerging treatment strategies may offer additional therapeutic options to address the unmet needs of these patients. Clinicians have recently been equipped with more treatment options, including janus kinase (JAK) inhibitors, and several more have just completed late stage clinical trials and are currently undergoing regulatory review. These new options have shown improved efficacy and safety in RA, and healthcare professionals should be educated on these options, guidelines, and strategies for implementing them into the treatment paradigm.

Upon completion of this activity, participants will be able to:

  • Assess new research findings on the pathogenesis of rheumatoid arthritis (RA), focusing on inflammatory signaling through Janus kinase (JAK) and interleukin (IL)-6 pathways

  • Recognize current and emerging janus kinases (JAK) inhibitors for RA in the context of selectivity, efficacy, safety, and clinical considerations for use

  • Identify patients with RA who would benefit from treatment with a JAK inhibitor

  • Employ new clinical trial data and evidence-based recommendations when making treatment decisions for individual patients with RA

  • Compare and contrast the economic benefits of JAK inhibitors for the treatment of RA, considering current comparative effectiveness research data and impact on medication adherence
     

Faculty: Maureen McMahon, MD, MS
Associate Chief, Division of Rheumatology
UCLA David Geffen School of Medicine

Disclosure:

Dr. McMahon has no relevant financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
AbbVie

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue